IP4 Stock Overview
A pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InnoCan Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.16 |
| 52 Week High | CA$0.35 |
| 52 Week Low | CA$0.13 |
| Beta | 3.07 |
| 11 Month Change | -15.80% |
| 3 Month Change | -26.14% |
| 1 Year Change | -0.31% |
| 33 Year Change | -48.41% |
| 5 Year Change | n/a |
| Change since IPO | 441.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| IP4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.6% | -4.8% | 0.8% |
| 1Y | -0.3% | -19.4% | 2.0% |
Return vs Industry: IP4 exceeded the German Pharmaceuticals industry which returned -19.4% over the past year.
Return vs Market: IP4 underperformed the German Market which returned 2% over the past year.
Price Volatility
| IP4 volatility | |
|---|---|
| IP4 Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IP4's share price has been volatile over the past 3 months.
Volatility Over Time: IP4's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Iris Bincovich | innocanpharma.com |
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.
InnoCan Pharma Corporation Fundamentals Summary
| IP4 fundamental statistics | |
|---|---|
| Market cap | €46.91m |
| Earnings (TTM) | -€4.85m |
| Revenue (TTM) | €17.61m |
2.7x
P/S Ratio-9.7x
P/E RatioIs IP4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IP4 income statement (TTM) | |
|---|---|
| Revenue | US$18.87m |
| Cost of Revenue | US$2.26m |
| Gross Profit | US$16.61m |
| Other Expenses | US$21.81m |
| Earnings | -US$5.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 88.04% |
| Net Profit Margin | -27.55% |
| Debt/Equity Ratio | 0% |
How did IP4 perform over the long term?
See historical performance and comparison